TextAE configuration unavailable!

PubMed:32343968 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id	Subject	Object	Predicate	Lexical cue
T1	7-18	DG_35	denotes	Tocilizumab
T2	23-31	SP_7	denotes	COVID-19
T3	99-110	NCBITaxon:11118	denotes	coronavirus
T4	125-133	SP_7	denotes	COVID-19
T5	194-202	SP_7	denotes	COVID-19
T6	257-263	NCBITaxon:9606	denotes	people
T7	289-297	SP_7	denotes	COVID-19
T8	348-356	GO:0019221	denotes	cytokine
T9	415-429	GO:0030097	denotes	hemophagocytic
T10	488-499	DG_35	denotes	tocilizumab
T11	504-508	PR:000001393	denotes	IL-6
T12	559-567	SP_7	denotes	COVID-19
T13	619-623	PR:000001393	denotes	IL-6
T14	715-723	SP_7	denotes	COVID-19
T15	765-776	DG_35	denotes	tocilizumab
T16	834-845	DG_35	denotes	tocilizumab
T17	865-870	NCBITaxon:10239	denotes	viral
T18	934-945	DG_35	denotes	tocilizumab
T19	966-974	SP_7	denotes	COVID-19
T20	1104-1115	DG_35	denotes	tocilizumab

hydroxychloroquine

Id	Subject	Object	Predicate	Lexical cue	hp_id
T1	40-65	Phenotype	denotes	Cytokine Release Syndrome	http://purl.obolibrary.org/obo/HP_0033041
T2	348-373	Phenotype	denotes	cytokine release syndrome	http://purl.obolibrary.org/obo/HP_0033041
T3	871-882	Phenotype	denotes	myocarditis	http://purl.obolibrary.org/obo/HP_0012819

Inflammaging

Id	Subject	Object	Predicate	Lexical cue
T1	0-66	Sentence	denotes	Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome:
T2	67-92	Sentence	denotes	A Cautionary Case Report.
T3	93-181	Sentence	denotes	Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China.
T4	182-274	Sentence	denotes	Since then, COVID-19 has become a pandemic affecting more than 1.5 million people worldwide.
T5	275-457	Sentence	denotes	Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH).
T6	458-654	Sentence	denotes	Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking.
T7	655-777	Sentence	denotes	We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab.
T8	778-987	Sentence	denotes	Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS.
T9	988-1144	Sentence	denotes	These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process.
T1	0-66	Sentence	denotes	Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome:
T2	67-92	Sentence	denotes	A Cautionary Case Report.
T3	93-181	Sentence	denotes	Novel coronavirus disease 2019 (COVID-19) emerged in late December 2019 in Wuhan, China.
T4	182-274	Sentence	denotes	Since then, COVID-19 has become a pandemic affecting more than 1.5 million people worldwide.
T5	275-457	Sentence	denotes	Patients with COVID-19 have a wide spectrum of manifestations, one being cytokine release syndrome (CRS) and its fatal correlate, secondary hemophagocytic lymphohistiocytosis (sHLH).
T6	458-654	Sentence	denotes	Anti-cytokine therapy such as tocilizumab, an IL-6 receptor antagonist, is a potential treatment for COVID-19; however, data regarding the efficacy of this anti-IL-6 therapy are currently lacking.
T7	655-777	Sentence	denotes	We report two cases of patients who received a diagnosis of COVID-19 complicated by CRS and were treated with tocilizumab.
T8	778-987	Sentence	denotes	Both patients progressed to sHLH despite treatment with tocilizumab, and one developed viral myocarditis, challenging the safety and clinical usefulness of tocilizumab in the treatment of COVID-19-induced CRS.
T9	988-1144	Sentence	denotes	These cases highlight the need for clinical trials to determine optimal patient selection and timing for the use of tocilizumab during this disease process.